KDR and ovarian cancer: The targeting of multiple signaling pathways such as VEGFR, EGFR, IL-6R-JAK-STAT3/NF-κB, PI3K/AKT/mTOR, and ABC drug transporters in ovarian cancer may be an auspicious start to favourable PFS and OS outcomes.